(CSTL) is a Great Momentum Stock: Should You Buy? (Zacks) Oct-20-24 05:00AM Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors (...
Castle Biosciences stock price target raised to $90 from $70 at KeyBanc Capital Feb. 3, 2021 at 5:58 a.m. ET by Tomi Kilgore Castle Biosciences started at overweight with $70 stock price target at KeyBanc Capital Nov. 10, 2020 at 6:30 a.m. ET by Tomi Kilgore Castle Bioscien...
Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High? Feb. 20, 2025 at 9:55 a.m. ETon Zacks.com Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up Feb. 20, 2025 at 8:54 a.m. ETon Zacks.com ...
Moreover, CSTL currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressiveexternally-audited track record, this is a more conclusive indication...